Overview
- Talazoparib taken with enzalutamide is available on the NHS from today for advanced or hormone‑relapsed prostate cancer.
- NICE estimates about 2,400 men in England each year will be eligible, primarily those unable to receive chemotherapy or other standard treatments.
- Clinical trials cited by NICE show overall survival of 45.8 months versus 37 months on enzalutamide alone, with progression‑free survival rising to 33.1 months from 19.5 months.
- The oral combination can be taken at home, offering a more convenient option while reducing hospital visits.
- Patient groups and the health secretary welcomed the decision, which follows rising prostate cancer diagnoses in the UK and ongoing discussions on screening and the National Cancer Plan.